ChromaVision's ACIS cleared in US for broader diagnosis
This article was originally published in Clinica
ChromaVision Medical Systems has received US FDA clearance to market its automated cellular imaging system (ACIS) for the analysis of immunohistochemical stains. The device, which already has 510(k) clearance for use with biochemical stains to screen blood for certain malignancies, can now be used to assess a wider spectrum of conditions including cancer and infectious diseases.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.